NCT01352520 2026-01-20
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT02588651 2025-11-21
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03187210 2025-03-30
BAL
Insel Gruppe AG, University Hospital Bern
Phase 1/2 Suspended
NCT03264131 2025-02-10
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02388490 2024-09-23
Bretuximab
Seoul National University Hospital
Phase 2 Completed
NCT02499627 2021-05-27
FIL-BBV
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
NCT02169505 2019-11-27
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02243436 2019-04-24
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Completed
NCT02567851 2018-05-11
BREVITY
University of Birmingham
Phase 2 Completed
NCT02408042 2017-06-27
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Western Regional Medical Center
Phase 1/2 Withdrawn
NCT01671813 2013-07-25
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Withdrawn